Completed × Methotrexate × Myeloid × Clear all
NCT02220985 2025-06-04

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Fred Hutchinson Cancer Center

Phase 2 Completed
84 enrolled
NCT01951885 2023-09-11

Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention

Case Comprehensive Cancer Center

Phase 3 Completed
101 enrolled 28 charts
NCT00045305 2023-06-28

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Eastern Cooperative Oncology Group

Phase 2 Completed
17 enrolled 10 charts
NCT01168219 2022-08-04

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
68 enrolled 11 charts
NCT02129582 2021-05-07

Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies

Case Comprehensive Cancer Center

Phase 1 Completed
14 enrolled
NCT00489203 2021-02-03

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 2 Completed
140 enrolled
NCT00741455 2020-11-23

Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

Dartmouth-Hitchcock Medical Center

Phase NA Completed
18 enrolled 7 charts
NCT01529827 2019-09-24

Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Roswell Park Cancer Institute

Phase 2 Completed
94 enrolled 11 charts
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
NCT01789255 2018-07-24

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

National Cancer Institute (NCI)

Phase 2 Completed
12 enrolled 11 charts
NCT00245037 2017-09-27

Bu Flu TBI

OHSU Knight Cancer Institute

Phase 1/2 Completed
147 enrolled 19 charts
NCT00448357 2017-07-17

LCCC0510

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Completed
54 enrolled 17 charts
NCT00448201 2017-05-30

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

UNC Lineberger Comprehensive Cancer Center

Phase 2 Completed
71 enrolled 12 charts
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00005988 2017-04-04

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Dana-Farber Cancer Institute

Phase 1 Completed
5 enrolled
NCT00053196 2016-07-01

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
82 enrolled
NCT00589563 2014-09-10

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

City of Hope Medical Center

Phase 2 Completed
32 enrolled 24 charts
NCT00003593 2013-06-27

Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome

Children's Oncology Group

Phase 3 Completed
254 enrolled
NCT00521430 2013-03-26

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

National Cancer Institute (NCI)

Phase NA Completed
30 enrolled
NCT00627666 2013-03-26

Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematological Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled
NCT00014469 2013-03-07

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
NCT00296023 2012-10-04

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

University of California, San Francisco

Phase NA Completed
25 enrolled
NCT00787761 2012-10-01

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Northside Hospital, Inc.

Phase 2 Completed
24 enrolled 13 charts